Cellestia Biotech Raises CHF 8M Seed Financing

Cellestia Biotech AG, a Basel, Switzerland – based private biopharmaceutical company with strategic focus on anti-cancer drugs modulating the NOTCH signaling pathway, closed a CHF8m financing round.
The total financing includes a CHF 0.5m Seed A round and a CHF 2.3m Seed B round conducted during 2016 and a just closed CHF 5.2m Seed C round.

Backers included PPF Group and several private investors. As part of the agreement, a representative of PPF Group will join the board of directors of Cellestia.

The company intends to use the funds to advance the lead product CB-103 and to conduct and complete a first-in-man phase I clinical study. The preparations for launching the clinical program in 2017 are ongoing.

Founded in 2014 as a spin-off from Ecole Polytechnique Fédérale de Lausanne, EPFL and led by Michael Bauer, CEO, Cellestia is advancing CB-103, a novel oral pan-NOTCH inhibitor for the treatment of NOTCH dependent leukemia, lymphoma and solid tumor indications. It has achieved a pre-clinical proof of concept, with efficacy demonstrated in vitro and in vivo in various animal models as well as ex vivo efficacy on leukemic blasts in the blood from pediatric leukemia patients. Preclinical studies demonstrated excellent efficacy and the compound´s safety profile is well understood.

The company holds a worldwide exclusive license on the intellectual property rights for CB-103 and related series of close analogues, for development and commercialization.

FinSMEs

27/01/2018

Join the discussion